David LinetskyPoint-of-Care Marketing
Paul TheisenPatient Acquisition
Liz KaneImpactful Strategy
Daniel SontupeMarket Access
Matthew DurhamOmnidynamic Marketing
Joey CohenMedication Adherence
Bud BilanichSuccess Coach
Matt TurnerPatient Affordability
Pat PurcellMeeting Engagement
Frank BurrellScientific Storytelling
Stacey GandlerBrand Nourishment
Amy GilesIncreasing Engagement
Suma Ramadas, PhDMedical Affairs
Brenda SnowAuthentic Patient Voice
YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email